The full U.S. House of Representatives hasn’t voted on any marijuana amendments since 2016, and it’s largely because of one man.
In his capacity as chairman of the House Rules Committee, Congressman Pete Sessions (R-TX) has enormous power over which measures make it to the floor for consideration by his colleagues.
Despite continued efforts from a large group of bipartisan representatives, Sessions’s panel has consistently blocked all cannabis proposals from advancing over the course of nearly two years.
In wide-ranging comments at a federal event on Tuesday, Sessions revealed the extent to which he disapproves of marijuana use and misunderstands scientific research about its effects.
“If addiction is the problem and we have marketers of addiction that include marijuana — because all you have to do is go to any of the stores in Colorado and they can give you high to low to medium to chocolate — we ought to call for it what it is,” he said, according to the Fort Worth Star-Telegram. “If it were nicotine, it would have been outlawed; well, it would have been handled differently. But this is a political issue.”
Saying he thinks there are “better alternatives [than marijuana to treat medical conditions],” Sessions’s view is that “we don’t have to go to that.”
And implying that marijuana use causes young people to do other drugs as well, he asked, “Where do they start? If it’s marijuana, we ought to stand up and be brave in the medical community to say this political direction is not right.”
Numerous studies have shown that cannabis has medical value for people suffering from a variety of conditions, and research has routinely debunked the so-called “gateway theory” about marijuana leading to use of other drugs.
Also at the event, hosted by the U.S. Department of Health and Human Services, Sessions claimed that the potency of marijuana has risen dramatically since he was a young man.
“I referred to marijuana as merchants, this is a merchants of addiction, they are making it more powerful and more powerful and more powerful,” he said, according to the Star-Telegram. “When I went to high school … in 1973, I graduated, marijuana, on average, is 300 times more powerful. That becomes an addictive element for a child to then go to the next thing.”
While studies have shown that the THC concentrations in cannabis have generally risen over the past several decades, the “300 times more powerful” figure isn’t supported by the research base. Taken at face value, the math would mean that cannabis plants are comprised of more than 100 percent THC, a physical impossibility.
Sessions Blocks All Marijuana Amendments
After years of trying and failing to pass cannabis amendments in Congress, reformers scored their first big federal legislative victory in 2014, when the House of Representatives passed a measure to block the Justice Department from interfering with state medical cannabis laws. The measure was enacted into law, and also approved the following year with an even bigger bipartisan margin of victory on the House floor.
In the two years that followed, representatives also approved measures to increase marijuana businesses’ access to banks and protect state industrial hemp research programs from federal intervention.
The last time the full House voted on marijuana, in May 2016, it approved a measure to allow military veterans to receive medical cannabis recommendations from U.S. Department of Veterans Affairs doctors.
But the next month, Sessions’s Rules Committee began its cannabis blockade by preventing measures on marijuana banking and letting Washington, D.C. spend its own money to regulate cannabis from advancing.
Since then, the panel has consistently blocked any and all marijuana amendments from moving to the floor, including ones to extend the existing medical cannabis protections and to allow marijuana providers to take tax deductions that are available to businesses in other industries.
The committee has also shut down measures to extend the existing state medical cannabis protections to cover laws that allow for recreational marijuana use. In 2015, that amendment came just nine flipped votes short of passage on the floor. The number of states with legalization has more than doubled since the last vote on it, so the proposal would almost certainly pick up support now that many more members of Congress represent businesses and consumers who would be protected by it.
But Sessions’s blockade has ensured that his colleagues haven’t been given another opportunity to consider it again.
While the decision to stop letting the House vote on marijuana measures came at the same time as leaders began shutting down amendments on other issues deemed to be controversial, such as gun control and LGBT rights, Sessions’s new comments at the HHS event show he has a particular concern about cannabis policy changes.
Personal Experience Informs Sessions’s Anti-Marijuana Views
Last month, just before blocking a new version of the amendment to protect broad state marijuana laws from advancing, the Texas Republican spoke about his distaste for marijuana.
“I, as probably everybody in this rooms knows, have a strong opinion on drugs, illegal drugs, alcohol,” he said. “Marijuana is an addictive product, and the merchants of addiction make it that way. They make it for addiction. They make it to where our people, our young people, become addicted to marijuana and keep going.”
And his position seems to be informed by the experiences of people who are close to him.
At the HHS event this week, Sessions spoke about cases of two individuals:
“A dear friend of mine, David Siegel, a wealthy man, one of the wealthiest men in America, had an 18-year-old daughter who was in treatment, I believe for marijuana and maybe cocaine,” Sessions said. “She met a boy there and within three weeks after being out she was dead. She came back and did what she had been doing after being off it.”
Sessions later told of a Boy Scout he knew in Lake Highland, who went off to school at Texas A&M, and fell into heavy drug use started by smoking marijuana. “Never had smoked marijuana,” Sessions said. “At the end of the first year, he was well into it; the second year, he was into heroin. The drive for addiction with some of our children is insatiable. You just never know when you’re looking at a kid what drives them. But parents are desperate.”
Sessions, like all members of the House, is up for reelection this year. The Cook Political Report, which tracks congressional races, currently rates the district as “Lean Republican.”
In the meantime, Sessions faces fellow Republican Paul Brown in a March 6 primary. Brown’s campaign website says the federal government “should not legislate…narcotics. Those should be legislated by states or localities if they are to be legislated at all.”
Congressman Earl Blumenauer (D-OR), one of the House’s leading advocates for marijuana policy reform, announced last year that his political action committee would pay to put up billboards in Sessions’s district criticizing his cannabis blockade.
The Texas congressman has no relation to U.S. Attorney General Jeff Sessions, also an ardent legalization opponent.
Virginia Has Sealed 64,000 Marijuana Distribution Charges Since Legalization Took Effect This Summer
“These aren’t just numbers and there are families attached.”
By Ned Oliver, Virginia Mercury
Virginia has sealed records documenting more than 64,000 misdemeanor marijuana distribution charges since the state legalized the drug in July.
The figure came out Thursday during a meeting of the legislature’s Cannabis Oversight Commission.
Officials said the records were scrubbed from the state’s criminal record database, which is used by employers like school boards, state agencies and local governments to screen employees.
The state had already sealed 333,000 records detailing charges of simple possession last year after the state reduced the offense to a civil infraction on par with a traffic offense, said Shawn G. Talmadge, the Deputy Secretary of Public Safety and Homeland Security.
Lawmakers directed the state to expand that effort when they voted to broadly legalize recreational use of marijuana earlier this year.
The legislature also agreed to a broader expungement reform that will automatically seal other misdemeanor charges, including underage possession of alcohol, use of a fake ID, petit larceny, trespassing and disorderly conduct. Talmadge said those charges will remain in the system until the state finishes updating the software it uses to track criminal records.
“As of right now, the process is proceeding,” he said.
The Virginia Joint Commission on Cannabis Oversight is meeting now. You can find the agenda and links to livestream and to provide public comment at https://t.co/f1wsPn7SV7
— Jennifer McClellan (@JennMcClellanVA) October 14, 2021
Members of the oversight commission also heard from two advocates who urged them to move fast to address people currently imprisoned for marijuana offenses—a category of people the legalization legislation passed this year did not address.
Chelsea Higgs Wise, the leader of the advocacy group Marijuana Justice, and Gracie Burger, with the Last Prisoner Project, said Department of Corrections data suggests there are currently 10 people being held solely on serious marijuana charges.
They said it remains unknown how many more are being held because of marijuana related probation violations.
“These aren’t just numbers and there are families attached,” Burger said.
DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone
The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year.
In a notice scheduled to be published in the Federal Register on Monday, the agency said there’s been a “significant increase in the use of schedule I hallucinogenic controlled substances for research and clinical trial purposes,” and it wants authorized manufacturers to meet that growing demand.
DEA had already massively upped its proposed 2021 quota for cannabis and psilocybin last month, but now it’s calling for significantly larger quantities of research-grade marijuana and a broader array of psychedelics to be manufactured in 2022.
It wants to double the amount of marijuana extracts, psilocybin and psilocyn, quadruple mescaline and quintuple DMT. What especially stands out in the notice is MDMA. The agency is proposing an enormous 6,300 percent boost in the production of that drug—from just 50 grams in 2021 to 3,200 grams in the coming year—as research into its therapeutic potential continues to expand.
LSD would see a 1,150 percent increase, up to 500 grams of the potent psychedelic.
Marijuana itself would get a 60 percent boost under DEA’s proposal, up to 3.2 million grams in 2022 from the 2 million grams last year.
Here’s a visualization of the proposed quota increase from 2021 to 2022 for marijuana and cannabis extracts:
For all other THC, psilocybin, psilocyn and MDMA:
And for other psychedelic substances like LSD, mescaline and DMT:
DEA said in the Federal Register notice that it has been receiving and approving additional applications to “grow, synthesize, extract, and manufacture dosage forms containing specific schedule I hallucinogenic substances for clinical trial purposes” to achieve these ambitious quotas.
“DEA supports regulated research with schedule I controlled substances, as evidenced by increases proposed for 2022 as compared with aggregate production quotas for these substances in 2021,” the agency said, adding that it working “diligently” to process and approve marijuana manufacturers applications in particular, as there’s currently only one farm at the University of Mississippi that’s permitted to cultivate the plant for research.
“Based on the increase in research and clinical trial applications, DEA has proposed increases in 3,4- Methylenedioxyamphetamine (MDA), 3,4-Methylenedioxymethamphetamine (MDMA), 5-Methoxy-N,N-dimethyltryptamine, Dimethyltryptamine, Lysergic acid diethylamide (LSD), Marihuana, Marihuana Extract, Mescaline, Psilocybin, Psilocyn, and All Other Tetrahydrocannabinols to support manufacturing activities related to the increased level of research and clinical trials with these schedule I controlled substances.”
Here are the exact numbers for the proposed 2021 and 2022 quotas:
|All other tetrahydrocannabinol||1,000||2,000|
A 30-day public comment period will be open after the notice is formally published on Monday.
It’s difficult to overstate just how significant the proposed 2022 increases are, but it’s certainly true that scientific and public interest in marijuana and psychedelics has rapidly increased, with early clinical trials signaling that such substances show significant therapeutic potential.
National Institute on Drug Abuse (NIDA) Director Nora Volkow told Marijuana Moment in a recent interview that she was encouraged by DEA’s previous proposed increase in drug production quota. She also said that studies demonstrating the therapeutic benefits of psychedelics could be leading more people to experiment with substances like psilocybin.
Advocates and experts remain frustrated that these plants and fungi remain in the strictest federal drug category in the first place, especially considering the existing research that shows their medical value for certain conditions.
A federal appeals court in August dismissed a petition to require the DEA to reevaluate cannabis’s scheduling under the Controlled Substances Act. However, one judge did say in a concurring opinion that the agency may soon be forced to consider a policy change anyway based on a misinterpretation of the therapeutic value of marijuana.
Separately, the Washington State attorney general’s office and lawyers representing cancer patients recently urged a federal appeals panel to push for a DEA policy change to allow people in end-of-life care to access psilocybin under state and federal right-to-try laws.
Image element courtesy of Kristie Gianopulos.
Supreme Court Won’t Hear Case On Legalizing Safe Drug Consumption Sites, But Activists Are Undeterred
The U.S. Supreme Court (SCOTUS) has rejected a request to hear a case on the legality of establishing safe injection sites where people can use illicit drugs in a medically supervised environment.
The justices announced on Tuesday that they decided against taking up the case raised by the nonprofit Safehouse, despite the pleas of attorneys general from 10 states and D.C. who recently filed amici briefs urging the court’s involvement.
Representatives from 14 cities and counties, as well as the mayor of Philadelphia, which is at the center of the current case, also filed briefs in support of the case in recent days.
Safehouse was set to launch a safe consumption site in Philadelphia before being blocked by a legal challenge from the Trump administration. It filed a petition with the nation’s highest court in August to hear the case.
But while the Supreme Court declined to take action—and the Biden administration passed up its voluntary opportunity to weigh in at this stage, which may well have influenced the justices’ decision—activists say the battle will continue at a lower federal court level, where the administration will have to file briefs revealing its position on the issue.
Disappointed but not surprised U.S. Supreme Court declined to hear our case. We’re pursuing our claims in federal court. As that litigation proceeds, Biden administration will have to take a position, which it avoided by waiving its right to respond to our Supreme Court petition.
— Safehouse (@SafehousePhilly) October 13, 2021
“We were disappointed that the government chose not to respond to our petition,” Safehouse Vice President Ronda Goldfein told Filter. “They said, ‘We’re going to waive our right to respond,’ [and] the Supreme Court declined to review our case. Ordinarily that sounds like the end of the road—but in our case we are still pursuing our claims in a different venue.”
That venue will be the the federal district court in Philadelphia, where activists plan to submit multiple arguments related to religious freedom and interstate commerce protections. The Biden administration will be compelled to file a response in that court by November 5.
“If they don’t respond, they lose,” Goldfein said.
A coalition of 80 current and former prosecutors and law enforcement officials—including one who is President Joe Biden’s pick for U.S. attorney of Massachusetts—previously filed a brief urging the Supreme Court to take up Safehouse’s safe injection case.
Fair and Justice Prosecution, the group that coordinated the amicus brief, also organized a tour of Portugal for 20 top prosecutors in 2019 so they could learn about the successful implementation of the country’s drug decriminalization law.
If the Supreme Court were to have taken the case and rule in favor of Safehouse, it could have emboldened advocates and lawmakers across the country to pursue the harm reduction policy.
The governor of Rhode Island signed a bill in July to establish a safe consumption site pilot program where people could test and use currently illicit drugs in a medically supervised environment. It became the first state in the country to legalize the harm reduction centers. It’s not clear whether the Department of Justice will seek to intervene to prevent the opening of such facilities in that state.
Massachusetts lawmakers advanced similar legislation last year, but it was not ultimately enacted.
A similar harm reduction bill in California, sponsored by Sen. Scott Wiener (D), was approved in the state Senate in April, but further action has been delayed until 2022.